Sequencing, Antibodies, Colon Cancer, Dual Labeled Nucleotides
Decisive Diagnostics has the rights to a large body of intellectual property through its parent company Catalyst Assets.
Whether your research involves sequencing or antibodies, we may be able to offer you licensing opportunities to our patented technologies and help you further your product development. Ask us about our patented colon cancer research. In a single assay you can determine both the microsatellite status of the cancer and whether microsatellite unstable (MSI) colon cancers are hereditary or sporadic.
Decisive Diagnostics has rights to novel dual labeled nucleotide designs (patent pending). These nucleotides can have applications in quantitative PCR, sequencing and beyond.